Newsenselab

Berlin, Germany

Pain Management Therapeutics Self-Care Patient Education

The Berlin health startup Newsenselab GmbH has developed M-sense Migraine, the first digital health application (DiGA) against migraines, which can be prescribed by doctors as an app on prescription and is subject to the highest safety standards. The app has been tested by the Federal Institute for Drugs and Medical Devices (BfArM) and has been reimbursed by all statutory health insurers since mid-December 2020 as part of the Digital Supply Act (DVG). M-sense Migraine combines a variety of non-drug therapy methods from clinical practice, based on the guidelines of modern migraine treatment - personalized, motivating and always available. The aim of the DiGA is to offer a personalized therapy to reduce attacks by analyzing the individual pain pattern. Newsenselab also conducts clinical studies with partners such as the Charité Universitätsmedizin Berlin and the University Clinics Halle and Rostock to examine the effectiveness of DiGAs in the treatment of chronic diseases. The first results of the migraine study EMMA, one of the first clinical studies to take place entirely online, will be published in 2022.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Newsenselab on @MedStartr Today #MigraineHeadache #PainManagement #NeurologicalDisorders #Therapeutics #SelfCare #PatientEducation #MedMo #MedStartrVentures

https://www.medstartr.ai/s/NF5-JBqvpFE

Get Involved in Newsenselab

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2016
Website: m-sense.de/

Disease Areas

Migraine & Headache Pain Management Neurological Disorders

Technologies

Digital Health PlatformsDisease Management SolutionsPatient Engagement Platform

🌐Website

What do you think of Newsenselab?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.